A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Rutgers Cancer Institute researchers awarded $2.3 million in American Cancer Society grantson November 19, 2019 at 6:22 am
Autophagy is required to maintain cellular metabolism, which may cause KRAS-mutant lung cancer to be resistant to chemotherapy or immunotherapy. If autophagy is blocked, anti-cancer therapies may be ...
- Doctors focus on treating nasty cancer side effectson November 19, 2019 at 3:07 am
Overall, cancer deaths in the United States have gone down for the past two decades, thanks in part to immunotherapy and specialized therapies. But those life-saving treatments sometimes come with a ...
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- Prostate cancer bone metastases thwart immunotherapy by producing TGF-betaon November 14, 2019 at 8:07 am
The discoveries by a team led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, explain why immunotherapy has been largely unsuccessful ...
- Cancer Immunotherapy Market Global Outlook by Size, Share, Trend, Growth, Demand, Industry Analysis, Business Strategies by 2023on November 13, 2019 at 5:28 pm
Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. Get Exclusive Free Sample Copy @ ...
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyon November 13, 2019 at 1:17 pm
Some cancer cells exploit these molecules to dial down immune attacks that would otherwise ... The 22-patient cohort was about age 67 on average and, as is typical of RA, three-quarters were women. RA ...
- Gene Modifying Immunotherapy for Blood Cancer Market to Expand on Account of Rising Research and Development Activities By 2027on November 13, 2019 at 2:36 am
Research Nester released a report titled “Gene Modifying Immunotherapy for Blood Cancer Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global gene ...
- Regular screening, immunotherapy among latest weapons against lung canceron November 12, 2019 at 2:00 pm
The chances of remission and recovery decline in later stage cancer, making the low-dose CT scan even more important. * I understand and agree that registration on or use of this site constitutes ...
- Cancer Immunotherapy Market 2019 Global Industry Overview Growth By 2024 – Market Research Engineon November 12, 2019 at 4:51 am
Nov 12, 2019 (Heraldkeepers) -- New York, November 12, 2019: The cancer immunotherapy market is segmented on the lines of its type, application, end user and regional. Based on type segmentation it ...
via Bing News